1. Home
  2. JELD vs MDXH Comparison

JELD vs MDXH Comparison

Compare JELD & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

N/A

Current Price

$1.54

Market Cap

168.8M

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

N/A

Current Price

$3.34

Market Cap

183.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
JELD
MDXH
Founded
1960
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Forest Products
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
168.8M
183.4M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
JELD
MDXH
Price
$1.54
$3.34
Analyst Decision
Hold
Strong Buy
Analyst Count
6
3
Target Price
$3.43
$7.67
AVG Volume (30 Days)
1.6M
110.0K
Earning Date
05-18-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,211,181,000.00
N/A
Revenue This Year
N/A
$30.31
Revenue Next Year
$2.31
$18.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.51
$1.36
52 Week High
$6.98
$5.33

Technical Indicators

Market Signals
Indicator
JELD
MDXH
Relative Strength Index (RSI) 26.92 42.88
Support Level N/A $3.05
Resistance Level $2.06 $3.78
Average True Range (ATR) 0.15 0.17
MACD -0.04 -0.02
Stochastic Oscillator 4.71 15.09

Price Performance

Historical Comparison
JELD
MDXH

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: